A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation

Summary

The purpose of this study is to determine the safety and effectiveness of administering Wilms tumor gene 1 (WT1) cancer peptides. Cancer peptides are short pieces of protein that are made in a laboratory to be like the peptides that can be found in cancer. These peptides are intended to be given as a "vaccine" to activate the immune cells in a person to attack his/her cancer. These peptides are mixed with an oily substance called Montanide ISA-51 and a white cell growth factor called Granulocyte-macrophage colony-stimulating factor (GM-CSF) which may help make the immune response stronger.

Timeline

Start

2007-06

Primary completion

2013-04

Completion

2013-10

Outcome

Outcome not reported

Stopped (Enrollment): “low accrual”

Drugs

Indications